Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2023.09.08.556913

Influence of FTDP-17 mutants on circTau RNAs

Margvelani, G.·Welden, J. R.·Arizaca Maquera, K. A.·Miranda Sardon, S.·Stamm, S.
View original source ↗Export metadata ↓

Abstract

At least 53 mutations in the microtubule associated protein tau gene (MAPT) have been identified that cause frontotemporal dementia. 47 of these mutations are localized between exons 7 and 13. They could thus affect the formation of circular RNAs (circRNAs) from the MAPT gene that occur through backsplicing from exon 12 to either exon 10 or exon 7. We analyzed representative mutants and found that five FTDP-17 mutations increase the formation of 127 circRNA and three different mutations increase the amount of 1210 circRNA. CircRNAs are translated after undergoing adenosine to inosine RNA editing, catalyzed by ADAR enzymes. We found that the interferon induced ADAR1-p150 isoform has the strongest effect on circTau RNA translation. ADAR1-p150 activity had a stronger effect on circTau RNA expression and strongly decreased 127 circRNA, but unexpectedly increased 1210 circRNA. In both cases, ADAR-activity strongly promoted translation of circTau RNAs. Unexpectedly, we found that the 127 circTau protein interacts with eukaryotic initiation factor 4B (eIF4B), which is reduced by four FTDP-17 mutations located in the second microtubule domain. These are the first studies of the effect of human mutations on circular RNA formation and translation. They show that point mutations influence circRNA expression levels, likely through changes in the secondary pre-mRNA structures. The effect of the mutations is surpassed by editing of the circular RNAs, leading to their translation. Thus, circular RNAs and their editing status should be considered when analyzing FTDP-17 mutations. HighlightsO_LI47/53 known FTDP-17 mutations are located in regions that could influence generation of circular RNAs from the MAPT gene C_LIO_LICircular Tau RNAs are translated after adenosine to inosine RNA editing, most effectively caused by ADAR1-p150 C_LIO_LIFTDP-17 mutations influence both circTau RNA and circTau protein expression levels C_LIO_LICircTau protein expression levels do not correlate with circTau RNA expression levels C_LIO_LICircTau proteins bind to eukaryotic initiation factor 4B, which is antagonized by FTDP-17 mutations in exon 10 C_LI Graphic Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=187 SRC="FIGDIR/small/556913v2_ufig1.gif" ALT="Figure 1"> View larger version (27K): org.highwire.dtl.DTLVardef@94a395org.highwire.dtl.DTLVardef@7fbdc3org.highwire.dtl.DTLVardef@83539eorg.highwire.dtl.DTLVardef@1e6b59e_HPS_FORMAT_FIGEXP M_FIG C_FIG

Source connections

Explore related subjects

molecular biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Margvelani, G., Welden, J. R., Arizaca Maquera, K. A., Miranda Sardon, S., Stamm, S.. 2023-09-09. Influence of FTDP-17 mutants on circTau RNAs. https://doi.org/10.1101/2023.09.08.556913

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Single-AAV-mediated cardiomyocyte-specific adenine base editing ameliorates cardiac hypertrophy in vivo

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, frequently accompanied by cardiac hypercontractility, diastolic dysfunction, heart failure and sudden cardiac death. The disease is predominantly caused by pathogenic variants in genes encoding sarcomeric proteins and current therapeutic strategies largely focus on symptom management. Adeno-associated virus-based (AAV) delivery of base editing tools has emerged as an alternative strategy that acts directly on the genetic cause of disease. However, canonical SpCas9-based editors are too large to package into a single-AAV vector which mandates dual-AAV approaches that require higher overall vector doses with elevated toxicity risk and increased manufacturing costs. Here, we report the development and application of a single vector approach for cardiomyocyte-specific adenine base editing to correct a Dutch founder mutation in MYBPC3 (c.2827C>T, p.Arg943Ter) that causes HCM. We systematically compared compact base editors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and selected the most efficient configuration, which reversed disease-associated hypercontractility in engineered human myocardium (EHM). To fit the editor/guide construct in a single-AAV vector, we screened a library of rationally designed small chimeric promoters and identified 6C2 to effectively drive expression in hiPSC-CMs and cardiac tissue of both mice and non-human primates (NHP) with exceptional specificity. Delivered in a single next-generation cardiotropic AAV capsid, we achieved therapeutic correction in an HCM mouse model at doses 20-fold below published dual-AAV cardiomyopathy base editing approaches. These results establish cardiomyocyte-specific, single vector-mediated base editing as a viable therapeutic strategy for inherited cardiomyopathies.

molecular biology↗
bioRxiv2026

Engineered Miniature ParTasR Enables Efficient PAMless Genome Editing

TIGR-Tas system holds great promise for genome-engineering applications owing to its compact size and PAMless targeting capability. However, its low editing efficiency in mammalian cells severely limits its broader utility. Here, we engineered a highly active variant of ParTasR, termed eTasR, through structure-guided rational design of ParTasR combined with fusion to the exonuclease TREX2. eTasR increased mammalian editing efficiency from the original 4.29% to 48.94% with an average 26.52-fold increase, significantly surpassing the efficiency of SpRY, a reported version of PAM-free nuclease. More importantly, single-AAV delivery enabled efficient Hpd disruption in vivo, resulting in robust phenotypic rescue. Thus, eTasR provides a compact, PAMless and highly efficient platform for genome editing and therapeutic applications.

molecular biology↗
bioRxiv2026

Enhancing pancreatic islet cell survival via NMDAR antagonist-driven ROR1 activation as revealed by phosphoproteomics

NMDA receptors (NMDARs) control function and survival not only of neurons, but also of insulin-producing pancreatic beta cells. Since insufficient insulin secretion and beta cell death are key events during diabetes development, targeting NMDARs offers a therapeutic approach. Specifically, the NMDAR antagonist dextrorphan (DXO) increases glucose-stimulated insulin secretion in clinical trials. Furthermore, treatment with DXO or optimized DXO derivatives prevents pancreatic islet cell death upon diabetogenic insults. Nonetheless, the signaling pathways induced by NMDAR inhibition are poorly understood. Here, we use complementary approaches, phosphoproteomics and tyrosine kinase profiling, to demonstrate that DXO and its derivatives rapidly regulate multiple intracellular signaling clusters, including mTOR and ERK signaling, in pancreatic islets. Notably, mTOR inhibition, but not ERK inhibition, is sufficient to negate DXO's protective effects. Further, we show that activation of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) is a universal event upon NMDAR inhibition in islets. Simultaneous knockdown of Ror1/ROR1 and its paralogue Ror2/ROR2 compromises the viability of both mouse and human islets, highlighting the ROR1/2 signaling axis as a promising avenue for enhancing beta cell survival.

molecular biology↗